Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of intravenous TAK-242 in acute alcoholic hepatitis with decompensated alcohol-related cirrhosis and acute-on-chronic liver failure
2019-001969-33Phase 2Unknown
- Sponsor
- Akaza Bioscience Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcoholic hepatitis (AH), alcoholic cirrhosis and acute-on-chronic liver failure (ACLF) comparing TAK-242 with Placebo (2 arms). Primary endpoint: Change in CLIF-C ACLF score from baseline to Day 8. Status: unknown.
02
Drugs
resatorvid
03
Conditions
alcoholic hepatitis (AH)alcoholic cirrhosisacute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on 2019-001969-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001969-33.